Search results for "amine"

showing 10 items of 7299 documents

Diagnostic problems and postnatal follow-up in congenital toxoplasmosis

2007

Aim. In order to assess the consequences of different clinica] approaches in the prenata] management of congenital toxoplasmosis, we retrospectively reviewed 58 pregnant women with Toxoplasma seroconversion and prospec­ tively enrolled their 59 infants, referred to us from 1999 to 2004. Metbods. Data on clinica!, laboratocy and de­ mographic characteristics of the pregnant women were collected. Their children were entered intoa 48-month follow-up progcamme in which clinica , instrumental, ophthalmo­ logic and serologic evaluations were carried out at birth, at 1, 3, 6, 9, 15, 18, 24, 36 and at 48 months of life. Paediatric treatment with Spiramycin alone or alternated with Pyrime­ thamine-S…

AdultAdolescentSettore MED/17 - Malattie InfettiveAntiprotozoal AgentsSulfadiazinePolymerase Chain ReactionToxoplasmosis CongenitalAntimalarialsPregnancyAnimalsHumansProspective StudiesSicilyRetrospective StudiesInfantToxoplasmosis Diagnostic stepsInfectious Disease Transmission VerticalPyrimethamineTreatment OutcomeImmunoglobulin MImmunoglobulin GPregnancy Complications ParasiticAmniocentesisCoccidiostatsDrug Therapy CombinationFemalePregnancy TrimestersBiomarkersFollow-Up Studies
researchProduct

PET Studies of Net Blood—Brain Clearance of FDOPA to Human Brain: Age-Dependent Decline of [18F]Fluorodopamine Storage Capacity

2005

Conventional methods for the graphical analysis of 6-[18F]fluorodopa (FDOPA)/positron emission tomography (PET) recordings ( Kappin) may be prone to negative bias because of oversubtraction of the precursor pool in the region of interest, and because of diffusion of decarboxylated FDOPA metabolites from the brain. These effects may reduce the sensitivity of FDOPA/PET for the detection of age-related changes in dopamine innervations. To test for these biasing effects, we have used a constrained compartmental analysis to calculate the brain concentrations of the plasma metabolite 3- O-methyl-FDOPA (OMFD) during 120 mins of FDOPA circulation in healthy young, healthy elderly, and Parkinson's …

AdultAgingFluorine Radioisotopesmedicine.medical_specialtyMetaboliteDiffusionCentral nervous system diseasechemistry.chemical_compoundDopamineInternal medicinemedicineHumans18F-fluorodopamineFluorodopamedicine.diagnostic_testbusiness.industryPutamenBrainHuman brainMiddle Agedmedicine.diseaseDihydroxyphenylalanineEndocrinologymedicine.anatomical_structureNeurologychemistryPositron emission tomographyPositron-Emission TomographyNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessmedicine.drugJournal of Cerebral Blood Flow & Metabolism
researchProduct

δ 1‐OPIOID receptor‐mediated controlofacetylcholine (ACh) release in human neocortex slices

1998

In slices of human neocortex, prelabelled with [3H]-choline, the release of [3H]-acetylcholine reflects the evoked release of endogenous acetylcholine which was elicited by the same electrical stimulation paradigm. [3H]-Acetylcholine release was depressed by the delta-opioid receptor agonist D-Pen2-D-Pen5-enkephalin. When the nerve endings were depolarized by elevating extracellular potassium the evoked [3H]-acetylcholine release was similarly depressed by D-Pen2-D-Pen5-enkephalin in the absence, but not in the presence, of tetrodotoxin which blocks action potential propagation. Therefore, the delta-opioid receptor inhibiting [3H]-acetylcholine release should not be located to cholinergic n…

AdultAgonistmedicine.medical_specialtymedicine.drug_classNarcotic AntagonistsNeocortexTetrodotoxinIn Vitro TechniquesOctreotideBenzylidene Compoundschemistry.chemical_compoundDevelopmental NeuroscienceInterneuronsOpioid receptorReceptors Opioid deltaInternal medicinemedicineHumansReceptorAgedAged 80 and overNeocortexEnkephalinsMiddle AgedReceptor antagonistAcetylcholineElectric StimulationNaltrexoneEndocrinologymedicine.anatomical_structurenervous systemchemistryTetrodotoxinCholinergicEnkephalin D-Penicillamine (25)-AcetylcholineDevelopmental Biologymedicine.drugInternational Journal of Developmental Neuroscience
researchProduct

Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis

1999

Nucleoside analogue-induced lactic acidosis is an often fatal condition in patients with HIV. There is only one report of successful treatment with riboflavin. We describe a 30-year-old female with AIDS and nucleoside analogue-induced lactic acidosis that exacerbated shortly after introducing total parenteral nutrition and reversed within hours after the addition of thiamine. Successful treatment of nucleoside analogue-induced lactic acidosis with a high dose of thiamine supports the hypothesis that vitamin deficiency is an important cofactor in the development of this rare and unpredictable condition in patients with HIV. We suggest that high dose B-vitamins should be given to any patient …

AdultAnti-HIV AgentsPharmacologymedicineHumansThiamineAcidosisAcquired Immunodeficiency SyndromeNucleoside analoguebusiness.industryfood and beveragesMetabolic acidosismedicine.diseaseDidanosineStavudineB vitaminsAnesthesiology and Pain MedicineBiochemistryLactic acidosisAcidosis LacticFemaleParenteral Nutrition TotalThiaminemedicine.symptombusinessSevere lactic acidosisNucleosidemedicine.drugEuropean Journal of Anaesthesiology
researchProduct

Mutational analysis of 105 mucopolysaccharidosis type VI patients

2007

Mucopolysaccharidosis type VI (MPS VI; Maroteaux-Lamy syndrome) is a lysosomal storage disorder caused by mutations in the N-acetylgalactosamine-4-sulfatase (arylsulfatase B, ARSB) gene. ARSB is a lysosomal enzyme involved in the degradation of the glycosaminoglycans (GAG) dermatan and chondroitin sulfate. ARSB mutations reduce enzyme function and GAG degradation, causing lysosomal storage and urinary excretion of these partially degraded substrates. Disease onset and rate of progression is variable, producing a spectrum of clinical presentation. In this study, 105 MPS VI patients—representing about 10% of the world MPS VI population—were studied for molecular genetic and biochemical parame…

AdultArylsulfatase BAdolescentN-Acetylgalactosamine-4-SulfataseMPS VIDNA Mutational AnalysisNonsense mutationMucopolysaccharidosis type VIBiologyPolymorphism Single NucleotideGenetic HeterogeneityAge DistributionGene FrequencyGenotypeGeneticsmedicineHumansMissense mutationGenetic TestingChildCells CulturedGenetics (clinical)mucopolysaccharidosis type VIGlycosaminoglycansGeneticsMucopolysaccharidosis VIGenetic heterogeneityMucopolysaccharidosis VIMiddle Agedmedicine.diseasearylsulfatase BMaroteaux–Lamy syndromeDisease ProgressionARSBMaroteaux-LamyHuman Mutation
researchProduct

Effect of histamine and histamine analogues on human isolated myometrial strips.

1992

1. The effect of histamine and histamine H1- and H2-receptor agonists on isolated myometrium strips of premenopausal women has been examined. The effect of acetylcholine was also determined. 2. Histamine, 2-pyridylethylamine, 4-methylhistamine and acetylcholine, but not dimaprit, produced a concentration-related contractile response in human isolated myometrial strips. Histamine also produced a further contraction in human isolated myometrial strips precontracted with KCl (55 mM). 3. The contractile response to histamine was antagonized by the histamine H1-receptor antagonist, clemizole (0.1 microM) but was potentiated by the histamine H2-receptor antagonist, ranitidine (10 microM). Clemizo…

AdultAtropinemedicine.medical_specialtyPyridinesMuscle RelaxationHistamine H1 receptorRanitidineHistamine agonistPotassium ChlorideHistamine Agonistschemistry.chemical_compoundHistamine receptorUterine ContractionHistamine H2 receptorInternal medicinemedicineHumansPharmacologyDose-Response Relationship DrugMethylhistaminesMuscle SmoothMiddle AgedDimapritAcetylcholineClemizoleEndocrinologyMuscle relaxationchemistryMyometriumBenzimidazolesFemaleHistamineHistamineResearch ArticleBritish journal of pharmacology
researchProduct

The influence of penbutolol and placebo on blood sugar levels and insulin consumption in the glucose-controlled insulin infusion system ("artificial …

1990

The aim of the study was to investigate the influence of 40 mg of the beta-blocker penbutolol (Betapressin TM; Hoechst Ltd., Frankfurt/Main) in comparison to placebo on the insulin consumption on the blood sugar profile in twelve insulin-dependent diabetes (IDDM) patients. The patients were treated with penbutolol and placebo for a period of three days, and then were examined with the help of the glucose-controlled insulin infusion system. The blood sugar profile and insulin consumption over a 24 hour period was not affected by either penbutolol or placebo, nor could any changes be measured in these parameters when measured after food intake. After a submaximal exercise load on the bicycle …

AdultBlood GlucoseMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentBlood sugarPhysical exercisePlaceboPlacebosCatecholaminesInsulin Infusion SystemsPenbutololDiabetes mellitusInternal medicineDrug DiscoverymedicineHumansInsulinBeta blockerExerciseGenetics (clinical)Artificial endocrine pancreasbusiness.industryInsulinGeneral Medicinemedicine.diseaseHormonesEndocrinologyDiabetes Mellitus Type 1Molecular MedicineFemalePenbutololbusinessmedicine.drugKlinische Wochenschrift
researchProduct

Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin lev…

2013

OBJECTIVE: Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly diagnosed prolactinoma in relation to disease control and CAB dosage. DESIGN: This is a retrospective clinical-based therapy analysis. PATIENTS: Forty-three patients with prolactinoma (eight men, 35 women), aged 33·65 ± 11·23 years, were evaluated metabolically at baseline and after 12 months of CAB treatment. MEASUREMENTS: Body mass index (BMI), systolic and diastolic blood pressure, waist circumference (WC), lipid profile, haemoglobinA1c (…

AdultBlood GlucoseMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPituitary neoplasmSettore MED/13 - EndocrinologiaBody Mass IndexYoung AdultEndocrinologyInsulin resistanceInternal medicineCabergolineMedicineHumansPituitary NeoplasmsProlactinomaErgolinesProlactinomaAdiposityRetrospective Studiesmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryInsulinmedicine.diseaseLipidsProlactinBlood pressureEndocrinologyDopamine AgonistsMetabolomeFemaleInsulin ResistanceWaist CircumferencebusinessLipid profileBody mass indexmedicine.drugClinical endocrinology
researchProduct

Results of an Open Clinical Trial of Brofaromine (CGP 11 305 A), a Competitive, Selective, and Short-Acting Inhibitor of MAO-A in Major Endogenous De…

1987

In an open clinical trial the authors treated 18 hospitalized patients suffering from endogenous depression with brofaromine (CGP 11305A), a competitive, selective, and short-acting inhibitor of type A monoamine oxidase (MAO). Four patients were defined as good responders, as they had a final HAMD score of between 0 and 7 points. Four patients were judged as improved, with final HAMD scores of between 8 and 15 points, while the remaining eight patients failed to respond (final HAMD score greater than or equal to 16 points). The major observations were a beneficial influence on drive in most patients, while paranoid symptoms worsened markedly, rendering the substance contraindicated in psych…

AdultBlood PlateletsMaleSerotoninMonoamine Oxidase Inhibitorsmedicine.medical_treatmentSleep REMTyraminePsychotic depressionPharmacologyPersonality AssessmentDexamethasonechemistry.chemical_compoundPiperidinesBrofaromineHamdmedicineHumansPharmacology (medical)Monoamine OxidaseDepression (differential diagnoses)AgedDepressive DisorderChemotherapybiologyElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthchemistryEndogenous depressionbiology.proteinFemaleMonoamine oxidase APsychologyPharmacopsychiatry
researchProduct

Inhibition of dextromethorphan metabolism by moclobemide.

1998

This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine. The subjects received seven oral doses of 20 mg dextromethorphan at 4-h intervals over 2 days (1 and 2) and subsequently moclobemide (300 mg b.i.d.) for 9 days. On days 10 and 11, they received seven doses of 20 mg dextromethorphan in addition to moclobemide. During monotreatment and combined treatment, blood was collected on days 2 and 11, respectively, for determination of dextromethorphan and its demethylated metabolites using automat…

AdultCYP2D6animal structuresMonoamine Oxidase InhibitorsAdolescentMoclobemidePharmacologyDextromethorphanchemistry.chemical_compoundPharmacokineticsOral administrationDextrorphanMoclobemideMedicineHumansDrug InteractionsBiotransformationPharmacologybusiness.industryDextromethorphanDrug interactionAntidepressive AgentsDebrisoquinechemistryArea Under CurveBenzamidesbusinessmedicine.drugPsychopharmacology
researchProduct